Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

National analysis of real-world racial and ethnic disparities in mortality, complications, and healthcare costs among adults hospitalized with newly diagnosed Acute Myeloid Leukemia

Mevlut Ozmen, Lavanya Nagarajan, Tanzeela Shuja et al. Nov 03, 2025 pp. 6397-6397 10.1182/blood-2025-6397

Abstract Background Impact Statement: This first nationally representative analysis focused exclusively on newly diagnosed AML demonstrates...

USP28 promotes multiple myeloma progression by regulating NF-κB signaling through KIF20B

Meng Chen, Fei Li Nov 03, 2025 pp. 7460-7460 10.1182/blood-2025-7460

Abstract Myeloma, as the second most common hematologic malignancy in the world, has seen significant improvements in prognosis due to the e...

Genomic heterogeneity and prognostic implications in CAR-t-treated relapsed/refractory primary CNS lymphoma

Miaomiao Cao, Hui Shi, Danyang Li et al. Nov 03, 2025 pp. 5489-5489 10.1182/blood-2025-5489

Abstract Background: In recent years, CAR-T therapy has gradually emerged as a treatment option for relapsed/refractory primary central nerv...

A VPAC1/2-targeted antagonist, preferentially binds to activated T cells and enhances T cell activation

Sonia Mecorapaj, Yuou Wang, Srijon Sarkar et al. Nov 03, 2025 pp. 2553-2553 10.1182/blood-2025-2553

Abstract Introduction: Vasoactive intestinal peptide (VIP) is an immunosuppressive neuropeptide signaling through VPAC1/VPAC2 receptors on T...

Health care resource utilization in patients with multiple myeloma receiving bispecific antibody therapy with teclistamab: A Medicare claims database analysis in the US

Sikander Ailawadhi, Thomas Delea, Olivier Humblet et al. Nov 03, 2025 pp. 3975-3975 10.1182/blood-2025-3975

Abstract Background: Four bispecific antibodies (bsAbs), teclistamab, elranatamab, talquetamab, and linvoseltamab have b...

Siltuximab-mediated suppression of CRP is associated with clinical response in idiopathic multicentric castleman disease

Jean-Francois Rossi, Azhaar Ashraf, Yildiz Kelahmetoglu et al. Nov 03, 2025 pp. 4788-4788 10.1182/blood-2025-4788

Abstract Introduction Idiopathic multicentric Castleman disease (iMCD) is a rare and serious disorder involving multicen...

Data update of a single-arm, Phase II Study of orelabrutinib with/without Rituximab in patients with chronic lymphocytic leukemia/small Lymphocytic Lymphoma after BTK inhibitor therapy

Linlin Cao, Hao Song, Guolin Wu et al. Nov 03, 2025 pp. 7416-7416 10.1182/blood-2025-7416

Abstract Background: Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is a common hematologic malignancy, and Bruton's tyro...

Long-term outcome and risk factors for relapse after allogeneic hematopoietic stem cell transplantation in myelofibrosis: Results from a large multicenter cohort

Julia-Annabell Georgi, Sebastian Stasik, Michael Krämer et al. Nov 03, 2025 pp. 1978-1978 10.1182/blood-2025-1978

Abstract Background Allogeneic hematopoietic stem cell transplantation (alloHCT) is increasingly performed in Myelofibro...

Outcomes after bone marrow versus peripheral blood mismatched unrelated donor hematopoietic cell transplantation using posttransplant cyclophosphamide-based GVHD prophylaxis

Amir Kasaeian, Moazzam Shahzad, Zeeshan Sattar et al. Nov 03, 2025 pp. 934-934 10.1182/blood-2025-934

Abstract BACKGROUND: Posttransplant cyclophosphamide (PTCy) is increasingly utilized as graft-versus-host disease (GVHD) prophylaxis in allo...

Safety of prothrombin complex concentrate for emergency surgery according to the oral factor xa inhibitor level

Ali Eshaghpour, Menaka Pai, Nicole Ibragimov et al. Nov 03, 2025 pp. 1346-1346 10.1182/blood-2025-1346

Abstract Background: The incidence of thrombotic events after use of 4-factor prothrombin complex concentrate (4F-PCC) for oral factor Xa in...

Efficacy and safety of ruxolitinib-based combination therapy in the patients with myelofibrosis (MF): A systematic review and meta-analysis

Shuai Tan, Yuxin Li, Yaofang Cao et al. Nov 03, 2025 pp. 7341-7341 10.1182/blood-2025-7341

Abstract ABSTRACT Background: Myelofibrosis (MF) is a chronic myeloproliferative neoplasm characterized by splenomegaly, anemia, bone marrow...

Thrombocytopenia at diagnosis adversely affects overall and leukemia-free survival in lower-risk MDS patients: A retrospective study from the FISiM registry

Anna Calvisi, Rosangela Filiberti, Daniela Barraco et al. Nov 03, 2025 pp. 2080-2080 10.1182/blood-2025-2080

Abstract Background Thrombocytopenia is a frequent hematologic abnormality in patients with myelodysplastic syndromes (MDS), occurring in ap...

Healthcare transition readiness for sickle cell disease: A high- and low- income comparative analysis

Kelly Pimenta, Jerlym Porter, Patricia Moura et al. Nov 03, 2025 pp. 4740-4740 10.1182/blood-2025-4740

Abstract Background: Sickle cell disease (SCD) is the most common inherited hemoglobinopathy globally, with the greatest burden in low- and...

Impact of cytoreduction on thrombotic and bleeding outcomes in patients with myeloproliferative neoplasms and atrial fibrillation

Carlos Patino, Cho Han Chiang, Rushad Patell et al. Nov 03, 2025 pp. 2690-2690 10.1182/blood-2025-2690

Abstract Background Myeloproliferative neoplasms (MPNs), such as polycythemia vera (PV) and essential thrombocythemia (ET) have an increased...

Cytokine receptor armored CAR-T cells enable robust T cell expansion and function in the absence of lymphodepletion

Lina Zhou, Jiapan Hu, wancheng yang et al. Nov 03, 2025 pp. 4104-4104 10.1182/blood-2025-4104

Abstract Chimeric antigen receptor (CAR) T cell therapy is emerging as a promising approach for oncology and autoimmune diseases. However, i...

First-in-human trial of siltuximab in combination with standard induction chemotherapy in patients with acute myeloid leukemia: The Phase 1 siltuxilam study.

Pierre Peterlin, Alice Garnier, Amandine Le Bourgeois et al. Nov 03, 2025 pp. 5193-5193 10.1182/blood-2025-5193

Abstract Background: Numerous studies have pointed out the pathological role of deregulated expression of Interleukin-6 (IL-6) in cancers. I...

Monocytosis as prognostic factor for chronic graft versus host disease

Cristina Marrero-Cepeda, Teresa Caballero-Velazquez, Francisco Manuel Martin-Dominguez et al. Nov 03, 2025 pp. 7760-7760 10.1182/blood-2025-7760

Abstract INTRODUCTION Chronic graft-versus-host disease (cGvHD) is the main cause of long-term morbidity and mortality a...

Lenalidomide (LEN) and anti-CD38 monoclonal antibodies (mAbs) utilization in patients with newly diagnosed and relapsed/refractory multiple myeloma (MM) in Germany: Real-world insights on epidemiology and clinical outcomes

Kai Strobel, Amol D. Dhamane, Jing Bo Li et al. Nov 03, 2025 pp. 4568-4568 10.1182/blood-2025-4568

Abstract Introduction: LEN has long been a foundational therapy in MM. Since the European approval of daratumumab and isatuximab, these anti...

Does stringent cytoreduction improve survival in myeloproliferative chronic myelomonocytic leukemia? a correlative study on the dacota trial.

Dorothée Selimoglu-Buet, Sylvie Chevret, Valeria Santini et al. Nov 03, 2025 pp. 791-791 10.1182/blood-2025-791

Abstract Background. Myeloproliferation at diagnosis is an adverse prognostic factor in CMML. Cytoreduction with hydroxyurea (HY) is conside...

Impact of obesity on outcomes of CAR T-cell therapy for hematologic malignancies: A real-world propensity-matched analysis

Mostafa Eysha, Mohanad Elchouemi, Usman Hussain et al. Nov 03, 2025 pp. 7682-7682 10.1182/blood-2025-7682

Abstract Background: Chimeric antigen receptor (CAR) T-cell therapy is a highly effective treatment for relapsed/refractory (R/R) hematologi...

Ornithine decarboxylase deficiency in donor T cells preserves strong GVL activity while attenuating acute and preventing steroid-resistant gut GVHD in a recipient tissue PD-L1-dependent manner

Qinjian Li, Boxi Lin, Yiwen Ling et al. Nov 03, 2025 pp. 5868-5868 10.1182/blood-2025-5868

Abstract Graft-versus-leukemia/lymphoma (GVL) activity and graft-versus-host disease (GVHD) are usually mediated by the same alloreactive T...

Early multi-immune modulation with rilzabrutinib in patients with primary ITP after first-line treatment failure: A phase 3b study (LUNA 4)

David Kuter, Waleed Ghanima, Nicola Cooper et al. Nov 03, 2025 pp. 4827-4827 10.1182/blood-2025-4827

Abstract Background: Immune thrombocytopenia (ITP) is driven by complex immune dysregulation involving both autoimmunity and inflammation, l...

An engineered AAVrh10 vector containing an optimized factor IX transgene improves therapeutic response during hemophilia b gene therapy

Shamshul Huda, Mohan Kumar, Dikshika Bihani et al. Nov 03, 2025 pp. 6091-6091 10.1182/blood-2025-6091

Abstract Background: Gene therapy using Adeno-associated virus (AAV) vectors has emerged as a promising alternative to frequent coagulation...

FLT3L-based conjugate targets chemoresistant leukemia stem cells via cell cycle re-entry in Acute Myeloid Leukemia

Dengyang Zhang, Yao Guo, Zhiyong Peng et al. Nov 03, 2025 pp. 319-319 10.1182/blood-2025-319

Abstract Acute myeloid leukemia (AML) is a genetically heterogeneous hematopoietic malignancy with poor prognosis. Standard cytotoxic chemot...

High prevalence of clonal hematopoiesis in fanconi anemia revealed by whole exome sequencing

Tiago Koppe, Felicia Andresen, Katie Frenis et al. Nov 03, 2025 pp. 745-745 10.1182/blood-2025-745

Abstract Fanconi anemia (FA) is an inherited bone marrow failure syndrome (IBMFS) characterized by hypersensitivity to DNA damage and a mark...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page